top of page

Cerebral Malaria Program  


Cerebral malaria kills over 300,000 children a year in Africa and ‘scientists have confirmed that malaria parasites in Africa have developed resistance to a key family of drugs used to protect against them.’  Nature, Sept 2021.

Novapep’s Professor Mosnier co-authored a review paper demonstrating why APC, which should be an effective therapy in cerebral malaria, does not work. The malaria parasite produces a protein which blocks APC’s activity  


The malaria parasite blocks the action of APC, but it cannot block G10’s mechanisms of action.

Novapep is developing a systemic form of G10 and Professor Mosnier is leading the G10 in cerebral malaria development activity.

Total funding for malaria control and elimination reached an estimated US$3 billion in 2019. Contributions from governments of endemic countries amounted to US$900 million, representing 31% of total funding. The WHO African Region carries a disproportionately high share of the global malaria burden.  In 2019, the region was home to 94% of malaria cases and deaths. Pricing of systemic G10 will have modest margin over costs of goods to ensure the drug can be provided to all those in need.

bottom of page